Implementing an IPTS Treatment Approach to Improve Outcomes in Suicidal Youth

October 30, 2019 updated by: Sunita Stewart, University of Texas Southwestern Medical Center

Implementing an Interpersonal Theory of Suicide Treatment Approach to Improve Outcomes in Suicidal Youth

The purpose of this project is to evaluate a set of interventions derived from a theory of suicide that supplements a clinical program and compare their effects on outcomes to the outcomes of the unsupplemented program. This study proposes to evaluate the effect of these interventions on reducing specific negative cognitions associated with depression and suicide ideation in an intensive outpatient program for suicidal youth (Suicide Prevention and Resilience at Children's, SPARC).

Study Overview

Status

Completed

Detailed Description

The trial will be conducted in a program where half of the clients are enrolled into either the original program (SPARC A which has a general focus on negative cognitions) or SPARC B (which will overlap significantly with SPARC A but targets in some sessions specific negative cognitions of perceived burdensomeness). The program is already structured so that each patient consistently attends either a morning or an afternoon track, with different therapists running each track. This allows for separate programs in each track. Clinically justifiable innovations are routinely introduced into the program usually in a stepwise fashion in one or another part by one set of therapists at a time. The investigators propose to take advantage of this partial introduction by assessing relative impact of SPARC A and SPARC B on depressive symptoms and suicide ideation. The investigators have no data to indicate that one program will be better than the other. The investigation will, however, allow the investigators to assess whether this innovation in fact is effective. Patients will not be randomized at the individual level, but rather their time slot (usually decided based on opening within the program) will place them into either SPARC A or SPARC B. The two programs are of identical length with numerous features in common, differing only in the specificity of the exercises and examples and their relevance to perceived burdensomeness. Routine assessments at entry and discharge from the program will not change based on study enrollment. However, suicide ideation, depressive symptoms, and negative cognitions (perceived burdensomeness and thwarted belongingness) will be more formally assessed at the one-month follow-up meeting or phone call which will add approximately 10 minutes to the contact.

Study Type

Interventional

Enrollment (Actual)

123

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Dallas, Texas, United States, 75235
        • Children's Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adolescents, ages 12 - 17
  • enrolled in the SPARC program at Children's Medical Center of Dallas
  • completed at least 5 SPARC group therapy sessions

Exclusion Criteria:

  • adolescents who have previously received treatment in the control arm of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SPARC A
SPARC A is an existing clinical program which has a general focus on negative cognitions.
SPARC A is an existing clinical program with a general focus on negative cognitions.
Experimental: SPARC B
SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Interpersonal Needs Questionnaire (INQ) (Van Orden et al., 2012)
Time Frame: through program completion, an average of 6 weeks
change in perceived burdensomeness
through program completion, an average of 6 weeks
Concise Health Risk Tracking Self Report (CHRT-SR) (Trivedi et al., 2011)
Time Frame: through program completion, an average of 6 weeks
suicide ideation (self-report)
through program completion, an average of 6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quick Inventory of Depressive Symptomatology - Adolescent Version Self-Report (QIDS-A-SR-16) (Bernstein et al., 2010)
Time Frame: through program completion, an average of 6 weeks
change in depressive symptoms
through program completion, an average of 6 weeks
Interpersonal Needs Questionnaire (INQ) (Van Orden et al., 2012)
Time Frame: 1 month after program completion
change in perceived burdensomeness
1 month after program completion
Concise Health Risk Tracking Self Report (CHRT-SR) (Trivedi et al., 2011)
Time Frame: 1 month after program completion
change in suicide ideation (self-report)
1 month after program completion
Quick Inventory of Depressive Symptomatology - Adolescent Version Self-Report (QIDS-A-SR-16) (Bernstein et al., 2010)
Time Frame: 1 month after program completion
change in depressive symptoms
1 month after program completion
Concise Health Risk Tracking Self Report (CHRT-SR)
Time Frame: between program completion, an average of 6 weeks, and 1 month after program completion
change in suicide ideation (self-report)
between program completion, an average of 6 weeks, and 1 month after program completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sunita M. Stewart, PhD, UT Southwestern Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 14, 2017

Primary Completion (Actual)

March 7, 2019

Study Completion (Actual)

June 1, 2019

Study Registration Dates

First Submitted

May 2, 2018

First Submitted That Met QC Criteria

May 15, 2018

First Posted (Actual)

May 17, 2018

Study Record Updates

Last Update Posted (Actual)

November 1, 2019

Last Update Submitted That Met QC Criteria

October 30, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • GA2016-010

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on SPARC A

Subscribe